Browse by Author

Browse by Year

Browsing publications by Emma Haagensen

Newcastle AuthorsTitleYearFull text
Emma Haagensen
The High-Affinity Interaction between ORC and DNA that Is Required for Replication Licensing Is Inhibited by 2-Arylquinolin-4-Amines2017
Zakareya Gamie
Emma Haagensen
Ricardo da Conceicao Ribeiro
Professor Kenneth Dalgarno
Dr Anja Krippner-Heidenreich
et al.
TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data2017
Emma Haagensen
Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing2016
Dr Gary Beale
Emma Haagensen
Huw Thomas
Lan Wang
Charlotte Revill
et al.
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer2016
Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-0372016
Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent2016
Emma Haagensen
Unreplicated DNA remaining from unperturbed S phases passes through mitosis for resolution in daughter cells2016
Emma Haagensen
Huw Thomas
Ian Wilson
Dr Suzannah Harnor
Sara Payne
et al.
The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice2013
Emma Haagensen
Suzanne Kyle
Dr Gary Beale
Dr Ross Maxwell
Professor Herbie Newell
et al.
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition2012